skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue

Original Research

(1829) Views  (384) Full article downloads

Authors: Thomas P Ahern, Mariann Christensen, Deirdre P Cronin-Fenton, et al

Published Date October 2010 Volume 2010:2 Pages 241 - 246
DOI: http://dx.doi.org/10.2147/CLEP.S13811

Thomas P Ahern1, Mariann Christensen2, Deirdre P Cronin-Fenton3, Kathryn L Lunetta4, Carol L Rosenberg5, Henrik Toft Sørensen3, Timothy L Lash3, Stephen Hamilton-Dutoit2
1Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts; 2Institute of Pathology; 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts; 5Hematology/Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

Objectives: Translational epidemiology studies often use archived tumor specimens to evaluate genetic hypotheses involving cancer outcomes. When the exposure of interest is a germline polymorphism, a key concern is whether the genotype assayed from tumor-derived DNA is representative of the germline. We evaluated the concordance between breast tumor-derived and normal lymph node-derived genotypes for three polymorphic tamoxifen-metabolizing enzymes.
Methods: We assayed paired DNA samples extracted from archived tumor and normal lymph node tissues from 106 breast cancer patients. We used TaqMan assays to determine the genotypes of three enzyme variants hypothesized to modify tamoxifen effectiveness, ie, CYP2D6*4, UGT2B15*2, and UGT1A8*2. We assessed genotype agreement between the two DNA sources by calculating the percent agreement and the weighted kappa statistic.
Results: We successfully obtained genotypes for CYP2D6*4, UGT2B15*2, and UGT1A8*2 in 99%, 100%, and 84% of the paired samples, respectively. Genotype concordance was perfect for the CYP2D6*4 and UGT1A8*2 variants (weighted kappa for both = 1.00; 95% confidence interval [CI] 1.00, 1.00). For UGT2B15*2, one pair out of 106 gave a discordant result that persisted over several assay repeats.
Conclusions: We observed strong agreement between DNA from breast tumors and normal lymphatic tissue in the genotyping of polymorphisms in three tamoxifen-metabolizing enzymes. Genotyping DNA extracted from tumor tissue avoids the time-consuming practice of microdissecting adjacent normal tissue when other normal tissue sources are not available. Therefore, the demonstrated reliability of tumor-derived DNA allows resources to be spent instead on increasing sample size or the number of polymorphisms examined.

Keywords: molecular epidemiology, breast neoplasms, cytochrome P450 CYP2D6, glucuronosyltransferase




 

Other articles by Dr Thomas Ahern



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Erratum
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Erratum
A case of recurrent bloody tears
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy